In melanoma, silencing of VEGF or TGF-β resulted in dramatically delayed tumor growth, associated with decreased Tregs and MDSCs and increased effector T-cell activation in tumor infiltrates, which restored tumor sensitivity to tumor-specific cell therapies and markedly improved the efficacy of anti-PD-1/anti-CTLA-4 treatment (93). Here, CTLA4 is linked to melanoma.